Avita Medical, Inc. (RCEL)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$10.16-2.40%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
Avita Medical is growing revenue from $17M to $82.5M in 2026. The new CEO and product traction support this growth. The company is improving despite losses. Debt deals and buybacks show financial moves to stabilize.
The company still loses money and missed earnings recently. Revenue growth may slow. Leadership changes add uncertainty.
The price is about 51% below our fair value near $10. Analysts expect 63% revenue growth. We see risk in profit and execution.
Breaks if: New debt issuance that increases financial risk materially
Breaks if: Progress score falls below 50% or leadership changes disrupt growth
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
RCEL represents a speculative growth investment with a focus on increasing revenue and improving margins. The current thesis state indicates a recent shift from robust to fragile, suggesting that the company's growth narrative has weakened.
The market seems to have priced in a justified valuation, but there is a notable expectations gap. RCEL is currently valued at a premium compared to its peers, indicating that investors may have high hopes for its future performance.
Management is focused on increasing revenue growth and improving gross profit margins, with recent results showing some progress. However, operating expenses management is lagging behind, which could impact overall profitability.
The future performance of RCEL hinges on several factors, including the ability to maintain revenue growth and manage expenses effectively. Additionally, the company's trajectory could be influenced by broader healthcare sector trends and the performance of key industry players.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent financial performance dropped from the top half to the bottom half of its industry. This change indicates the reason to own it has weakened. The market has not reacted clearly, with only a modest price movement since then.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Drive sustained revenue growth through expanded adoption of RECELL, Cohealyx, PermeaDerm, and international markets.
Stated as a priority in 2 of last 2 quarters. Revenue grew from $19.3 million in 2026-Q1 to $21.7 million in 2026-Q2, an 18% year-over-year increase and 13% sequential growth. Management emphasizes growth driven by RECELL and portfolio expansion, and the trajectory is delivering.
“Revenue grew 18% year-over-year and 13% sequentially quarter-over-quarter to a record $21.7 million.”
“Total revenue of approximately $19.3 million, up 4% year-over-year and approximately 10% sequentially.”
Breaks if: EPS loss worsens beyond -$0.5 next quarter
Breaks if: Revenue falls below $70M in FY26
Drive sustained revenue growth through expanded adoption of RECELL, Cohealyx, PermeaDerm, and international markets.
Stated as a priority in 2 of last 2 quarters. Revenue grew from $19.3 million in 2026-Q1 to $21.7 million in 2026-Q2, an 18% year-over-year increase and 13% sequential growth. Management emphasizes growth driven by RECELL and portfolio expansion, and the trajectory is delivering.
“Revenue grew 18% year-over-year and 13% sequentially quarter-over-quarter to a record $21.7 million.”
“Total revenue of approximately $19.3 million, up 4% year-over-year and approximately 10% sequentially.”
Over the next 1 to 3 years, RCEL's outlook will depend on its execution of management priorities and external market conditions. Not investment advice.